Chiglitazar

Drug Profile

Chiglitazar

Alternative Names: CS-038

Latest Information Update: 15 Sep 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Chipscreen Biosciences
  • Class Antihyperglycaemics; Carbazoles; Propionic acids; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor delta agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Type 2 diabetes mellitus
  • Preclinical Parkinson's disease

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 15 Sep 2016 Chiglitazar is still in phase III trials for Type-2 diabetes mellitus in China (PO)
  • 01 Jun 2014 Chipscreen Biosciences initiates enrolment in the phase III CMAS trial for Type-2 diabetes mellitus in China (NCT02173457)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top